Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update

Century Therapeutics, Inc. (NASDAQ:IPSC) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 3,090,000 shares, an increase of 14.0% from the December 15th total of 2,710,000 shares. Currently, 8.9% of the company’s stock are short sold. Based on an average daily volume of 560,600 shares, the short-interest ratio is presently 5.5 days.

Institutional Trading of Century Therapeutics

Several large investors have recently modified their holdings of IPSC. Wellington Management Group LLP acquired a new stake in shares of Century Therapeutics during the 3rd quarter worth $284,000. Bank of New York Mellon Corp grew its holdings in shares of Century Therapeutics by 110.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after purchasing an additional 78,088 shares in the last quarter. State Street Corp grew its holdings in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Century Therapeutics by 257.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock worth $123,000 after purchasing an additional 51,664 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Century Therapeutics by 283.6% during the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after purchasing an additional 45,797 shares in the last quarter. 50.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IPSC has been the topic of a number of research analyst reports. HC Wainwright dropped their price target on Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Piper Sandler dropped their price target on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. Finally, Chardan Capital dropped their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $10.00.

Century Therapeutics Stock Up 0.5 %

IPSC stock traded up $0.00 during trading hours on Friday, hitting $0.91. 373,338 shares of the stock were exchanged, compared to its average volume of 547,848. The company has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.59. Century Therapeutics has a 12 month low of $0.87 and a 12 month high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08. The firm had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.47 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. During the same quarter last year, the business earned ($0.55) EPS. On average, equities analysts anticipate that Century Therapeutics will post -1.63 earnings per share for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.